[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metronomic-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metronomic-chemotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100053538","phase-2-toripalimab-combined-with-beat-chemotherapy-in-the-treatment-of-advanced-back-line-small-cell-lung-cancer-100053538",false,"NCT07698054","Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","Inclusion Criteria:\n\n* 1.Age ≥18 years old, both male and female are acceptable.\n* 2\\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards:\n\n  1. always has not received the immune therapy,\n  2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \\> 3 months, withdrawal time \\> 3 months)\n  3. never used anlotinib,\n* 3\\. ECOG: 0 \\~ 2;\n* 4 . The expected lifetime 12 weeks or more;\n* 5\\. Major organs function normal\n\nExclusion Criteria:\n\n* 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;\n* 2.With known the special ripley sheet resistance, etoposide contraindication;\n* 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.","ALL","18 Years",{"count":19,"type":20},130,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.",[26,27,28],"SCLC, Extensive Stage","Bayesian","Metronomic Chemotherapy","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-08-01",{"date":37,"type":20},"2030-12-31",{"name":39,"class":40},"Henan Cancer Hospital","OTHER_GOV"]